NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After BCMA CART Therapy for RRMM
NCT05336383: Phase 2: Phase II Study of Salvage Radiation Treatment After B-cell Maturation Antigen Chimeric Antigen Receptor T-cell...
Dec 1, 2022
50
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release
NCT05347485: Phase 2: A Study of JNJ-68284528 Out-of-Specification (OOS) for Commercial Release in Participants With Multiple Myeloma The...
Dec 1, 2022
167
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program Post CART
NCT05064787: Evaluating the Feasibility of a Digital Health Coaching Program for Individuals Following CAR T Therapy The aim of this...
Dec 15, 2021
86
NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an Anti-BCMA Allogeneic CAR T Cell RRMM
IGNITE STUDY - ALLO-605: IGNITE STUDY UTILIZING FIRST TurboCAR™ TO TARGET BCMA NCT05000450: Phase 1/2: Safety and Efficacy of ALLO-605 an...
Dec 11, 2021
257
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Multiple Myeloma, Lymphoma, Leukemia
NCT05153330: Phase 1: Study of BMF-219, in Adult Patients With Acute Leukemia, Diffuse Large B-Cell Lymphoma and Multiple Myeloma...
Dec 10, 2021
87
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Myeloma With Isatuximab
NCT05053607: Real World Insights During Treatment for Relapsed/Refractory Multiple Myeloma With Isatuximab NCT05053607: Real World...
Dec 10, 2021
73
NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies
NCT05136807: Quality of Life in Patients With Asymptomatic Monoclonal Gammopathies NCT05136807: Quality of Life in Patients With...
Dec 10, 2021
115
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and RR DLBCL
NCT05121103: Phase 1: A Study in Subjects With Relapsed/Refractory Multiple Myeloma and Relapsed/Refractory Diffuse Large B-Cell Lymphoma...
Dec 1, 2021
147
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With RRMM
NCT04879043: Phase 1/2: Study to Assess Safety of HDP-101 in Patients With Relapsed Refractory Multiple Myeloma This study will assess...
Jun 18, 2021
228
Expanded Access Protocol for Receiving Idecabtagene Vicleucel That is Nonconforming for commercial
NCT04771078: Expanded Access Protocol (EAP) for Participants Receiving Idecabtagene Vicleucel That is Nonconforming for Commercial...
Jun 12, 2021
159
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies
NCT04354246: Phase 1: COM902 (A TIGIT Inhibitor) in Subjects With Advanced Malignancies COM902 (A TIGIT Inhibitor) in Subjects With...
Dec 19, 2020
63
NCT04268498: Phase2 - Daratumumab, Carfilzomib, Lenalidomide, Dex NDMM Multiple Myeloma (ADVANCE)
The ADVANCE trial Dara-KRd KRd VRd NCT04268498: A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With...
Dec 1, 2020
1,130
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, Oral RAD51 Inhibitor, in B-Cell Malignancies
NCT03997968: Phase 1/2: A Phase 1/2 Study of CYT-0851, an Oral RAD51 Inhibitor, in B-Cell Malignancies and Advanced Solid Tumors A Phase...
Dec 20, 2019
113
NCT04133636: Phase 2 - Study of JNJ-68284528, CAR-T Therapy Directed Against BCMA in MM -CARTITUDE-2
CARTITUDE-2 Ciltacabtagene Autoleuce A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell...
Dec 19, 2019
779
NCT03901963: Phase 3 - Dara + Len vs Len as Maint. in New Myeloma +MRD after frontline ASCT (AURIGA)
AURIGA Study A Study of Daratumumab Plus Lenalidomide Versus Lenalidomide Alone as Maintenance Treatment in Participants With Newly...
Dec 18, 2019
1,084
NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maint. NDMM DRAMMATIC
DRAMMATIC SWOG S1803 NCT04071457: Phase 3: S1803, Lenalidomide +/- Daratumumab/rHuPh20 as Post-ASCT Maintenance for MM w/MRD to Direct...
Dec 14, 2019
1,218
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma
NCT04136756: Phase 1 - NKTR-255 in Relapsed/Refractory Multiple Myeloma & Non-Hodgkin Lymphoma NKTR-255 in Relapsed/Refractory Multiple...
Dec 13, 2019
139
NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory
(LUMMICAR STUDY 2) NCT03915184: Phase 1 - Clinical Trial to Evaluate CT053 in Patients With Relapsed and/or Refractory Multiple Myeloma...
Dec 13, 2019
372
NCT03937635: Phase 3 - Lenalidomide, Dex +/- Daratumumab in High-Risk Smoldering Myeloma DETER-SMM
DETER-SMM EAA173 Lenalidomide, and Dexamethasone With or Without Daratumumab in Treating Patients With High-Risk Smoldering Myeloma...
Dec 12, 2019
746